Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Erratum to: Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide Combination Therapy in Patients with Hypertension Not Controlled with Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy: Results of a Randomized, Double-Blind, Multicenter Trial

Erratum to: Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine, and... Am J Cardiovasc Drugs (2016) 16:139 DOI 10.1007/s40256-016-0167-2 ERRATUM Erratum to: Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide Combination Therapy in Patients with Hypertension Not Controlled with Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy: Results of a Randomized, Double-Blind, Multicenter Trial 1 1 2 3 • • • • Il Suk Sohn Chong-Jin Kim Byung-Hee Oh Taek-Jong Hong 4 5 6 • • • Chang-Gyu Park Byung-Soo Kim Woo-Baek Chung For the Investigators Published online: 18 March 2016 Springer International Publishing Switzerland 2016 Erratum to: Am J Cardiovasc Drugs group (both p \ 0.0001 vs. baseline; p \ 0.0001 between DOI 10.1007/s40256-015-0156-x groups). Results, Section 3.2 Efficacy, para 1, lines 2–3 which Errors have subsequently been identified in the original previously read: publication, and the following corrections should be noted: After 8 weeks of double-blind treatment, the changes in Abstract, Results section, lines 9–11 which previously msDBP were -9.50 (8.46) mmHg in the OM/AML/HCTZ read: group and -4.23 (7.41) mmHg in the OM/HCTZ group (both p\ 0.0001 vs. baseline; p\ 0.0001 between groups; After 8 weeks of double-blind treatment, the changes in Fig. 2a). msDBP were -9.50 (8.46) mmHg in the OM/AML/HCTZ group and -4.23 (7.41) mmHg http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cardiovascular Drugs Springer Journals

Erratum to: Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide Combination Therapy in Patients with Hypertension Not Controlled with Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy: Results of a Randomized, Double-Blind, Multicenter Trial

Download PDF
1 page

Erratum to: Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide Combination Therapy in Patients with Hypertension Not Controlled with Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy: Results of a Randomized, Double-Blind, Multicenter Trial

Abstract

Am J Cardiovasc Drugs (2016) 16:139 DOI 10.1007/s40256-016-0167-2 ERRATUM Erratum to: Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide Combination Therapy in Patients with Hypertension Not Controlled with Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy: Results of a Randomized, Double-Blind, Multicenter Trial 1 1 2 3 • • • • Il Suk Sohn Chong-Jin Kim Byung-Hee Oh Taek-Jong Hong 4 5 6 • • •...
Loading next page...
 
/lp/springer-journals/erratum-to-efficacy-and-safety-study-of-olmesartan-medoxomil-a5f50H1wb0

References (2)

Publisher
Springer Journals
Copyright
Copyright © 2016 by Springer International Publishing Switzerland
Subject
Medicine & Public Health; Cardiology; Pharmacotherapy; Pharmacology/Toxicology
ISSN
1175-3277
eISSN
1179-187X
DOI
10.1007/s40256-016-0167-2
pmid
26994003
Publisher site
See Article on Publisher Site

Abstract

Am J Cardiovasc Drugs (2016) 16:139 DOI 10.1007/s40256-016-0167-2 ERRATUM Erratum to: Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide Combination Therapy in Patients with Hypertension Not Controlled with Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy: Results of a Randomized, Double-Blind, Multicenter Trial 1 1 2 3 • • • • Il Suk Sohn Chong-Jin Kim Byung-Hee Oh Taek-Jong Hong 4 5 6 • • • Chang-Gyu Park Byung-Soo Kim Woo-Baek Chung For the Investigators Published online: 18 March 2016 Springer International Publishing Switzerland 2016 Erratum to: Am J Cardiovasc Drugs group (both p \ 0.0001 vs. baseline; p \ 0.0001 between DOI 10.1007/s40256-015-0156-x groups). Results, Section 3.2 Efficacy, para 1, lines 2–3 which Errors have subsequently been identified in the original previously read: publication, and the following corrections should be noted: After 8 weeks of double-blind treatment, the changes in Abstract, Results section, lines 9–11 which previously msDBP were -9.50 (8.46) mmHg in the OM/AML/HCTZ read: group and -4.23 (7.41) mmHg in the OM/HCTZ group (both p\ 0.0001 vs. baseline; p\ 0.0001 between groups; After 8 weeks of double-blind treatment, the changes in Fig. 2a). msDBP were -9.50 (8.46) mmHg in the OM/AML/HCTZ group and -4.23 (7.41) mmHg

Journal

American Journal of Cardiovascular Drugs – Springer Journals

Published: Mar 18, 2016

There are no references for this article.